Astrazeneca Share News (AZN)

TOP NEWS: AstraZeneca hails heart-focused Forxiga approval in China

(Alliance News) - AstraZeneca PLC on Friday said its drug Forxiga has been approved in China for some adults to reduce the risk of cardiovascular death and hospitalisation.

FTSE 100 hits one-month low as record UK wage growth drives pound higher

UK basic wage growth hits record

*

Murphy Canyon to hold meeting on planned buy of interest in AZD1656

(Alliance News) - Cizzle Biotechnology PLC and Vela Technologies PLC on Tuesday noted that blank-check special purpose acquisition company Murphy Canyon Acquisition Corp will hold a special meeting on September 7.

LONDON MARKET MIDDAY: FTSE 100 flat, peers and pound up before US data

(Alliance News) - London's FTSE 100 underwhelmed on Thursday, as a slew of its heavyweights went ex-dividend, though blue-chip equities in mainland Europe were higher, showing no signs of pre-US inflation data angst and overlooking an acceleration in tensions between the world's two largest economies.

China's CanSino in mRNA vaccine deal with AstraZeneca

SHANGHAI, Aug 8 (Reuters) - CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.

UK dividends calendar - next 7 days

UK's FTSE 100 ends flat as BOJ sparks rate worries, higher on the week

AstraZeneca boosts pharma index to one-month high

*

European shares slip overall but German blue-chips hit record high

STOXX 600 dips 0.2% but posts weekly gains

*

AstraZeneca Q2 results beat estimates; COVID vaccine sales dry up

Q2 sales and earnings beat estimates

*

AstraZeneca's rare disease arm in $1 bln deal for Pfizer gene therapies

July 28 (Reuters) - AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the British drugmaker bets on new genetic therapies.

LONDON MARKET OPEN: StanChart, AstraZeneca lift FTSE 100 into green

(Alliance News) - Stock prices in London opened higher on Friday, boosted by a mostly strong set of company earnings, while investors weighed recent central bank decisions.

TOP NEWS: AstraZeneca profit surges as Alexion agrees Pfizer deal

(Alliance News) - AstraZeneca PLC on Friday reported half-year profit more than quintupling amid much lower costs, as its rare disease focused unit Alexion signed an agreement with Pfizer.

LONDON BRIEFING: NatWest posts interim growth; IAG swings to profit

(Alliance News) - Stocks in London are called slightly lower on Friday, with investors having plenty to consider amid the week's swathe of corporate earnings and central bank decisions.

AstraZeneca posts strong first half despite Covid drug weakness

(Sharecast News) - Pharmaceuticals giant AstraZeneca reported strong first-half growth on Friday, despite challenges related to the decline of Covid-19 medicines.

IN BRIEF: Astra drug approved while another shows promise

AstraZeneca PLC - Cambridge-based pharmaceutical firm - Says Soliris approved in EU for treatment of refractory generalised myasthenia gravis in those aged between six and 17. "This is the first and only targeted therapy approved for the treatment of paediatric patients with the disease in the EU," AstraZeneca says. Myasthenia gravis is a disease that causes muscle weakness. Separately, Astra says Enhertu shows meaningful progression-free survival and overall survival in some cancer sufferers. The measures are two secondary endpoints of a phase II trial. Enhertu is being jointly-developed by Astra and Daiichi Sankyo Co Ltd.